OMGA News and Press, Omega Therapeutics Inc. From 09/25/23

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference ...

2023-09-20 10:00:02 ET More on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutive week Wolfe Research stays defensive as it says markets wi...

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR Newswire CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda K...

Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D. Michelle C. Werner, CEO of Alltrna, Appointed to Board of Directors CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical...

2023-08-10 17:57:14 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . EBIX ( EBIX ) +3% . Innodata  ( INOD ) +12% . Consolidated Water ( CWCO ) +8% . Omega Therapeutics ( OMGA ) +5% . Losers: Biote  ( BTMD ) ...

2023-08-03 17:29:51 ET Omega Therapeutics press release ( NASDAQ: OMGA ): Q2 GAAP EPS of -$0.54 misses by $0.04 . Revenue of $0.76M (+58.3% Y/Y) beats by $0.33M . For further details see: Omega Therapeutics GAAP EPS of -$0.54 misses by $0.04, revenue of $...

Continued Enrollment in Monotherapy Dose Escalation Stage of Phase 1/2 MYCHELANGELO™ I Study; Preliminary First-in-Human Safety, Tolerability, Pharmacologic and Translational Data Anticipated in the Fourth Quarter of 2023 Presented New Preclinical Data at the American Society of Cl...

2023-08-01 16:29:26 ET Summary OMGA has an early stage program targeting various cancers using epigenetics. They are backed by a VC and have a decent cash runway. Though too early stage for my liking, OMGA is interesting. Omega Therapeutics ( OMGA ) develops epig...

2023-07-12 17:31:16 ET Gainers: Evolus ( NASDAQ: EOLS ) +5% . Omega Therapeutics ( OMGA ) +5% . Kodiak Sciences ( KOD ) +4% . Amazon ( AMZN ) +4% . Cara Therapeutics ( CARA ) +3% . Losers: ViaSat ( VSAT ) -7% ...

CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Chris Schade to its B...